Apr. 10, 2014
Exosect recently announced the appointment of Rob Cannings as Director of Business Development. Following Exosect’s recent announcement of its move to a licensing business model, Rob will lead the Business Development team and be responsible for out-licensing Exosect’s proprietary formulation delivery platforms, Entostat and Entomag.
Rob brings with him over 25 years of global biological and agrochemical experience across a wide range of markets, most recently the marketing of biopesticides within Bayer. His previous roles have included Product, Portfolio and Technology management roles in Agraquest, Chemtura, Scotts, Zeneca and ICI.
Exosect’s CEO, Martin Brown, comments, “Rob has a great deal of experience in both the synthetic and biological pesticide markets. He is therefore very well placed to drive out-licensing projects on our technology platforms. We are very pleased to welcome him to the team”